ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
E555163
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5932680 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals Context triple: [ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals, relatedTo, ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals]
-
A.
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
-
B.
Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
-
C.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
D.
Centre for Drug Safety
The Centre for Drug Safety is a specialized unit within the Norwegian Institute of Public Health that focuses on monitoring, researching, and improving the safe use of medicines.
-
E.
ICH E2A Clinical Safety Data Management
ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals Target entity description: ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
-
A.
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
-
B.
Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
-
C.
Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
-
D.
Centre for Drug Safety
The Centre for Drug Safety is a specialized unit within the Norwegian Institute of Public Health that focuses on monitoring, researching, and improving the safe use of medicines.
-
E.
ICH E2A Clinical Safety Data Management
ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
ICH guideline
ⓘ
nonclinical safety guideline ⓘ regulatory guideline ⓘ |
| addresses |
biological activity and potency testing in nonclinical programs
ⓘ
carcinogenicity testing considerations for biotechnology-derived products ⓘ dose selection for nonclinical studies ⓘ duration of nonclinical studies ⓘ genotoxicity testing considerations for biotechnology-derived products ⓘ immunogenicity assessment in nonclinical studies ⓘ local tolerance testing for biotechnology-derived products ⓘ reproductive toxicity testing considerations for biotechnology-derived products ⓘ safety assessment of impurities in biotechnology-derived products ⓘ safety evaluation of cytokines and growth factors ⓘ safety evaluation of monoclonal antibodies ⓘ safety evaluation of recombinant proteins ⓘ safety pharmacology considerations for biotechnology-derived products ⓘ selection of relevant animal species ⓘ species specificity of biotechnology-derived products ⓘ toxicology study design for biotechnology-derived pharmaceuticals ⓘ use of pharmacologically relevant animal models ⓘ |
| aimsTo |
harmonize international requirements for nonclinical safety testing of biotechnology-derived pharmaceuticals
ⓘ
reduce duplication of nonclinical studies across regions ⓘ |
| appliesTo |
biotechnology-derived pharmaceuticals
ⓘ
monoclonal antibodies ⓘ therapeutic proteins ⓘ |
| covers |
biomarker use in nonclinical safety studies
ⓘ
first-in-human dose selection considerations for biotechnology-derived products ⓘ study endpoints relevant to biotechnology-derived products ⓘ translation of nonclinical findings to clinical risk assessment ⓘ |
| documentType | scientific guideline ⓘ |
| focusesOn |
nonclinical safety testing requirements
ⓘ
preclinical safety evaluation ⓘ |
| hasAbbreviation |
ICH S6
ⓘ
linked to:
ICH
|
| hasVersion |
ICH S6(R1)
ⓘ
linked to:
ICH
|
| issuedBy | International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use ⓘ |
| language | English ⓘ |
| region |
European Union
ⓘ
Japan ⓘ United States ⓘ
linked to:
United States of America
|
| relatedTo |
ICH M3 Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization
ⓘ
ICH Q5 series guidelines on quality of biotechnological products ⓘ |
| supports |
clinical development of biotechnology-derived pharmaceuticals
ⓘ
marketing authorization of biotechnology-derived pharmaceuticals ⓘ |
| targetAudience |
nonclinical safety scientists
ⓘ
regulatory affairs professionals ⓘ |
| updateOf | original ICH S6 guideline ⓘ |
| usedBy |
biotechnology companies
ⓘ
pharmaceutical companies ⓘ regulatory authorities ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals Description of subject: ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
→
relatedTo
→
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
ⓘ